# A Stratified Sickle Event Randomized Trial (ASSERT)

> **NCT00102791** · PHASE3 · TERMINATED · sponsor: **Icagen** · enrollment: 297 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** ICA-17043

## Key facts

- **NCT ID:** NCT00102791
- **Lead sponsor:** Icagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-02
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 297 (ACTUAL)
- **Why stopped:** Because of the low probability of achieving the primary endpoint.
- **Last updated:** 2008-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102791, "A Stratified Sickle Event Randomized Trial (ASSERT)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00102791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*